2-溴-3,5-二甲氧基苯甲酸 | 941576-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-溴-3,5-二甲氧基苯甲酸
• 英文名称: 1-methyl-5-trimethylsilanylethynyl-1H-indole
• 英文别名: 1-methyl-5-((trimethylsilyl)ethynyl)-1H-indole；1-methyl-5-[(trimethylsilyl)ethynyl]indole；trimethyl-[2-(1-methylindol-5-yl)ethynyl]silane
• CAS: 941576-03-0
• 化学式: C₁₄H₁₇NSi
• 分子量: 227.381
• InChiKey: MHVUJTAUVYHNNT-UHFFFAOYSA-N

物化性质

• 沸点：
  315.0±24.0 °C(Predicted)
• 密度：
  0.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.41
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-溴-3,5-二甲氧基苯甲酸 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以117 mg的产率得到5-乙炔基-1-甲基-1H-吲哚
  参考文献：
  名称：

  Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

  摘要：

  A structure activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo-[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

  DOI：

  10.1021/jm200454y
• 作为产物：
  描述：

  5-碘吲哚 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 、 potassium hydroxide 作用下， 以 丙酮 为溶剂， 反应 26.0h， 生成 2-溴-3,5-二甲氧基苯甲酸
  参考文献：
  名称：

  具有抗癌特性的双吲哚烯炔的合成

  摘要：

  DOI：

  10.1016/j.jics.2023.101028

文献信息

• Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors
  申请人：KOZIKOWSKI Alan P.

  公开号：US20100004308A1

  公开（公告）日：2010-01-07

  Compounds of formula: and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's disease, amylotrophic lateral sclerosis (ALS), AIDS-associated dementia, diabetes, particularly type II diabetes, cardiomycete hypertrophy, reperfusion/ischemia, cancer, particularly colorectal cancer, pancreatic cancer, allergies and/or asthma and hair loss or baldness.

  该化合物的公式：以及其药学上可接受的盐、酯和溶剂化物，其中变量在说明书中定义，通常用作蛋白激酶抑制剂，特别是用于抑制GSK-3。提供了含有发明化合物的药学组合物和药物。本发明提供了治疗蛋白激酶相关疾病、紊乱或病况的方法。本发明提供了治疗GSK-3相关疾病、紊乱或病况的方法。更具体地，本发明提供了治疗双相情感障碍、包括躁狂、精神分裂症、中风、癫痫、运动神经元疾病、头部或脊柱创伤、神经退行性疾病、包括多发性硬化症（MS）、阿尔茨海默病、脆性X综合征、自闭症、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症（ALS）、艾滋病相关痴呆、糖尿病，特别是II型糖尿病、心肌肥厚、复灌/缺血、癌症，特别是结肠癌、胰腺癌、过敏和/或哮喘以及脱发或秃发的方法。
• Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors
  申请人：The Board of Trustees of the University of Illinois

  公开号：US08207216B2

  公开（公告）日：2012-06-26

  Compounds of formula: and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's disease, amylotrophic lateral sclerosis (ALS), AIDS-associated dementia, diabetes, particularly type II diabetes, cardiomycete hypertrophy, reperfusion/ischemia, cancer, particularly colorectal cancer, pancreatic cancer, allergies and/or asthma and hair loss or baldness.

  此处提供的化合物公式为：和其药用可接受的盐、酯和溶剂化物，其中变量定义在说明书中，通常用作蛋白激酶抑制剂，特别适用于GSK-3的抑制。本发明提供了含有该化合物的药物组合物和药物。本发明提供了治疗蛋白激酶相关疾病、疾病或病况的方法。本发明提供了治疗GSK-3相关疾病、疾病或病况的方法。更具体地，包括躁狂症、精神分裂症、中风、癫痫、运动神经元疾病、头部或脊柱创伤、神经退行性疾病，包括多发性硬化症（MS）、阿尔茨海默病、脆性X综合症、自闭症、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症（ALS）、艾滋病相关痴呆、糖尿病，特别是2型糖尿病、心肌肥厚、再灌注/缺血、癌症，特别是结肠癌、胰腺癌、过敏和/或哮喘以及脱发或秃发的治疗方法。
• Visible-Light-Mediated Deacylated Alkynylation of Unstrained Ketone
  作者：Hao Wu、Shuguang Chen、Dengmengfei Xiao、Feng Li、Kaiyuan Zhou、Xiaocui Yin、Chunni Liu、Xinwei He、Yongjia Shang

  DOI：10.1021/acs.orglett.3c00145

  日期：2023.2.24

  Deconstructive alkynylation of an unstrained ketone catalyzed by an organic photocatalyst under blue light irradiation is reported for the first time. A broad substrate scope with up to 63 examples, excellent functional group tolerance, and gram scale reaction demonstrated the practicality of this novel alkynylation method. The dihydroquinazolinone derivative of trifluoroacetophenone had been proved

  首次报道了在蓝光照射下由有机光催化剂催化的未应变酮的解构炔基化。具有多达 63 个实例的广泛底物范围、出色的官能团耐受性和克级反应证明了这种新型炔基化方法的实用性。三氟苯乙酮的二氢喹唑啉酮衍生物在与各种炔基溴化物的三氟甲基化反应中表现良好，已被证明具有作为新型三氟甲基化试剂的潜力。
• 三环类化合物、其药物组合物及其应用
  申请人：[en]CHOLESGEN (SHANGHAI) CO.LTD.;[zh]珂阑（上海）医药科技有限公司

  公开号：WO2024140595A1

  公开（公告）日：2024-07-04

  本发明公开了一种三环类化合物、其药物组合物及其应用。具体地，本发明公开了一种如式(I)所示的化合物或其药学上可接受的盐。本发明所述的如式(I)所示的化合物或其药学上可接受的盐具有以下一个或多个优点：具有良好的SMO抑制性；表现出良好的Hh信号通路抑制能力；具有良好的肝微粒体代谢稳定性。
• Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists
  作者：Kuntarat Arunrungvichian、Valery V. Fokin、Opa Vajragupta、Palmer Taylor

  DOI：10.1021/acschemneuro.5b00058

  日期：2015.8.19

  Three series of substituted anti-1,2,3-triazoles (IND, PPRD, and QND), synthesized by cycloaddition from azide and alkyne building blocks, were designed to enhance selectivity and potency profiles of a lead alpha 7 nicotinic acetylcholine receptor (alpha 7-nAChR) agonist, TTIn-1. Designed compounds were synthesized and screened for affinity by a radioligand binding assay. Their functional characterization as agonists and antagonists was performed by fluorescence resonance energy transfer assay using cell lines expressing transfected cDNAs, alpha 7-nAChRs, alpha 4 beta 2-nAChRs, and 5HT(3A), receptors, and a fluorescence cell reporter. In the END series, a tropane ring of TTIn-1, substituted at Ni, was replaced by mono- and bicyclic amines to vary length and conformational flexibility of a carbon linker between nitrogen atom and Ni of the triazole. Compounds with a two-carbon atom linker optimized binding with K-d's at the submicromolar level. Further modification at the hydrophobic indole of TTIn-1 was made in PPRD and QND series by fixing the amine center with the highest affinity building blocks in the IND series. Compounds from IND and PPRD series are selective as agonists for the alpha 7-nAChRs over alpha 4 beta 2-nAChRs and 5HT(3A) receptors. Lead compounds in the three series have EC50's between 28 and 260 nM. Based on the EC50, affinity, and selectivity determined from the binding and cellular responses, two of the leads have been advanced to behavioral studies described in the companion article (DOI: 10.1021/acschemneuro.5b00059).